Navigation Links
New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace

e deaths among women than all other causes of maternal mortality combined and is the leading infectious cause of death in people with HIV/AIDS. The global economic toll of TB is at least $12 billion each year. The bacteria that cause TB, known as Mycobacterium tuberculosis (M.tb), can reside latent in the human body for many years, but once active, attack the respiratory system, and are easily spread through the air like the common cold -- by coughing and sneezing. The WHO estimates that one third of the world is infected with M.tb.

The last class of TB drugs was developed and approved in the 1960s, and the lengthy treatment (6-9 months) required by the old regimen is hindering the progress of TB control. Public health experts agree that a faster-acting TB cure would improve compliance, lower relapse rates, reduce the growth of drug resistant TB, reduce health care costs and save millions of lives. Novel new TB drugs also are needed to be compatible with antiretroviral drugs used to treat HIV for the rising number of those co-infected with TB and HIV, as well as to work against the deadly climb in drug resistant TB.

About the Global Alliance for TB Drug Development

The Global Alliance for TB Drug Development (TB Alliance) is a not-for- profit, product development partnership accelerating the discovery and/or development of new TB drugs that will shorten treatment, be effective against susceptible and resistant strains, be compatible with antiretroviral therapies for those HIV-TB patients currently on such therapies, and improve treatment of latent infection.

Working with public and private partners worldwide, the TB Alliance is leading the development of the most comprehensive portfolio of TB drug candidates in history, and is committed to ensuring that approved new regimens are affordable, adopted and available to those who need them.

The TB Alliance operates with funding from the Bill & Melinda Gates Foundation, Irish Aid, th
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... not always keep hands injury-freeLAS VEGAS, Feb. 27 ... on the rise in recent years, with more than ... Many of those injuries might be prevented with better ... the 2009 Annual Meeting of the American Academy ...
... Fenofibrate treatment reduces,cardiovascular disease (CVD) ... the,composite of cardiovascular death, myocardial infarction, ... patients with type 2 diabetes and,atherogenic ... high triglyceride (2.3,mmol/L-200mg/dL or higher) and ...
Cached Medicine Technology:Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 2Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 3Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 5Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 6
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter TUESDAY, ... have abstained from sex for one year will be allowed to ... that would reverse a 31-year ban on donations from men who ... announced Tuesday its intention to release a new draft guidance in ... from gay men. The FDA is changing its policy based ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle ... News) -- Teens are more likely to start smoking ... attention-deficit hyperactivity disorder (ADHD) or conduct disorder, new ... counsel families about the risk of substance use as ... Brinkman, research director at Cincinnati Pediatric Research Group, which ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... Washington University School of Medicine in St. Louis have ... it may sound, can be an essential approach to ... culture plates containing tumor cells to see if the ... one substance had scored a hit by inhibiting growth ...
... ... Food, Water and Essentials to about 300,000 Children and Families, , ... Port-au-Prince, Haiti (Vocus) February 9, 2010 -- One ... reached nearly 300,000 children and adults in the earthquake impact zone. , , , , ...
... insert them , TUESDAY, Feb. 9 (HealthDay News) -- Larger ... profit are more likely to use feeding tubes in patients ... prolong life or help with bed sores and other problems. ... more about which hospital you go to than a decision-making ...
... , , Give a ... Diabetes Kitchen" Cookbook , CHICAGO , Feb. 9 ... for the heart with the new cookbook "The Heart-Smart Diabetes Kitchen: Fresh, ... (ADA) and CanolaInfo. Whether you cook some of these recipes for love or ...
... Boston University,s Slone Epidemiology Center have found a direct ... 2 diabetes in African American women. The study, which ... , is the first prospective study to examine the ... 2 diabetes in a large, geographically diverse cohort of ...
... , , Passage of Problem-Riddled Health Freedom ... & Thousands of Jobs , BOISE, Idaho , ... laying the groundwork to oppose a non-existent federal health care law, ... to come.  AARP is calling the Idaho Health Freedom Act (House ...
Cached Medicine News:Health News:Researchers discover new way to kill pediatric brain tumors 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 3Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Neighborhood socioeconomic status and diabetes 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4
... Electric Micro Sagittal Saw, ... 6 deg. arc. Head rotates ... any angle, and our unique ... slippage. Can also be purchased ...
... The Brasseler USA™ Battery ... quickly and efficiently determine ... STR-2000, STR-3000 Extended Run, ... Driver™, Battery Packs contain ...
... Brasseler USA™ 2002 Battery Charger is manufactured to ... 2002 Battery Charger can charge up to four ... The 2002 Charger is designed to operate on ... is a malfunction in the operation of the ...
... contain rechargeable nickel cadmium battery cells. Heat ... battery life. Strict adherence to recommended autoclave ... recommendations will shorten battery life. Warning: Battery ... of the Battery Packs to autoclave conditions ...
Medicine Products: